Related Experiment Videos

[Control of tumor-related angiogenesis]

T Oikawa1

  • 1Department of Cancer Therapeutics, Tokyo Metropolitan Institute of Medical Science (Rinshoken), Japan. oikawa@rinshoken.or.jp

Human Cell
|June 11, 1999
PubMed

Insights

Researchers identified novel low molecular weight compounds, including microbial metabolites and retinoids, that inhibit tumor angiogenesis, metastasis, and growth. These findings pave the way for developing effective anti-angiogenic cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Tumor angiogenesis is crucial for cancer progression, including growth, invasion, and metastasis.
  • Targeting tumor angiogenesis is a key strategy for developing novel cancer treatments.
  • Effective anti-angiogenic therapies depend on the development of potent angiogenesis inhibitors.

Purpose:

  • To discover novel angiogenesis inhibitors using in vivo assays.
  • To identify low molecular weight compounds with anti-angiogenic, anti-metastatic, and/or anti-tumor activities.
  • To explore the potential of microbial metabolites, retinoids, and steroids as anti-angiogenic agents.

Summary:

  • Three in vivo assays were employed to screen for novel angiogenesis inhibitors.
  • Low molecular weight agents, such as microbial metabolites, retinoids, and steroids, demonstrated significant anti-angiogenic, anti-metastatic, and/or anti-tumor activities.
  • The study highlights the therapeutic potential of these compounds in cancer treatment.

Impact:

  • Identified promising candidates for the development of new anti-angiogenic cancer drugs.
  • Provides a foundation for further research into the mechanisms of these novel inhibitors.
  • Contributes to the ongoing effort to improve cancer treatment strategies through targeted therapies.

Related Concept Videos